SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

Morphic Medical has obtained an EU CE mark for RESET, a device designed to target the underlying cause of obesity and type 2 ...

Some weight loss drugs may cause hair loss. While it’s typically a temporary side effect, it can affect your confidence.

New data from The Ohio State University Wexner Medical Center Comprehensive Transplant Center shows obese patients with end stage kidney disease and diabetes can safely use weight loss injections to ...

A new Irish health clinic is set to make ‘fat jabs’ more accessible to those battling obesity. But the top medic leading the ...

Medicine, lifestyle changes, and surgery can return glucose levels to normal or nearly normal in some type 2 diabetes ...

Most individuals with chronic kidney disease (CKD) are unaware of their disease, according to a KDIGO controversies conference on CKD prevention.

For people beginning their weight loss journey, a combination of physical activity and a healthy diet – such as the ...

Abstract and Introduction Objective: To evaluate the effect of combination therapy with pioglitazone and glucagon-like peptide (GLP)-1 in patients with type 2 diabetes.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.